Table 3.
Summary of meta-analyses of colistin monotherapy versus colistin combination therapy for the treatment of multidrug-resistant gram-negative bacteria infections.
| Author/Pathogen | Clinical Improvement | Microbiological Response | 14-Day Mortality | * Hospital Mortality | Nephro-Toxicity | Combination Antibiotics |
|---|---|---|---|---|---|---|
| Chen/AB | No | Yes | No data | No | No data | RIF, SUL, CAR, TGC UNA, CPZ, AMG, TZA MIN, TMP |
| Zusman, O.,/GNB1 [34] | No data | No data | No data | No | No data | CAR, TGC, RIF, AMG, SUL, VAN, TZA, FOS |
| Kengkla, K.,/AB [35] | No | Yes % | No data | No | No | RIF, TGC, CAR, SUL, AMG, CPZ, UNA, FOS, MIN, TMP, TZA, |
| Vardakas, K.Z.,/GNB1 [36] | No data | No data | No data | No | No data | RIF, CAR, AMG, TGC, FOS, SUL, CIP |
| Cheng, I.L.,/GNB2 [37] | No data | No | No data | No | No | RIF, FOS, MPM, UNA |
| Wang, J.,/AB [38] | No | Yes | No data | No | No | CAR or/and Sul (subgroup analysis) |
| Schmid, A.,/AB [39] | No | No data | No data | No | No data | RIF, SUL, CAR, TGC UNA, AMG, TZA, RIF, |
| Samal, S.,/GNB1 [40] | No data | No data | No data | No | No data | RIF, VAN, TGC, CAR, SUL, AMG, CPZ, UNA, TAZ, FOS, MIN, TMP. |
* Hospital mortality or 28-day mortality. % Colistin in combination with sulbactam was associated with a significantly higher microbiological response than colistin monotherapy, AB: Acinetobacter baumannii, GNB1: Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa, GNB2: Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae. MPM: meropenem, SUL: sulbactam, CAR: carbapenem, TGC: tigecycline, AMG: aminoglycosides, FOS: fosfomycin, RIF: rifampicin, CPZ: cefperazone/sulbactam, UNA: ampicillin/sulbactam: MIN: minocycline, TAZ: piperacillin/tazobactam, TMP:TMP/SMX, CIP: ciprofloxacin, VAN: Vancomycin.